Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates

Stock Track

03/01

Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.

In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.

Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1166577550"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1166577550\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1166577550?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 04:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166577550","market":"hk","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.</p>\n\n<p>In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.</p>\n\n<p>Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-03-01 04:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.</p>\n\n<p>In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.</p>\n\n<p>Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1166577550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166577550","pubTimestamp":1740775716,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc.  saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"Arcutis Biotherapeutics因强劲的盈利和积极的临床更新而飙升5.08%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.\nIn its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.\nAdding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}